Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Non-Current Liabilities (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $15.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 32.47% year-over-year to $15.7 million, compared with a TTM value of $15.7 million through Dec 2025, up 32.47%, and an annual FY2025 reading of $15.7 million, up 32.47% over the prior year.
  • Total Non-Current Liabilities was $15.7 million for Q4 2025 at SAB Biotherapeutics, down from $16.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $31.9 million in Q4 2021 and bottomed at $4.3 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $15.2 million, with a median of $15.2 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities surged 466.41% in 2022, then plummeted 41.17% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $31.9 million in 2021, then plummeted by 38.73% to $19.5 million in 2022, then decreased by 23.86% to $14.9 million in 2023, then fell by 20.39% to $11.8 million in 2024, then surged by 32.47% to $15.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SABS at $15.7 million in Q4 2025, $16.0 million in Q3 2025, and $16.1 million in Q2 2025.